<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="369580">
  <stage>Registered</stage>
  <submitdate>5/11/2015</submitdate>
  <approvaldate>11/11/2015</approvaldate>
  <actrnumber>ACTRN12615001234505</actrnumber>
  <trial_identification>
    <studytitle>Evaluation of optical coherence (OCT), imaging to examine the structure and form of coronary plaques following a heart attack. </studytitle>
    <scientifictitle>Evaluation of optical coherence tomography (OCT) to examine the structure and form of the coronary plaque in patients follwing a non-ST elevation myocardial infarction (NSTEMI). </scientifictitle>
    <utrn />
    <trialacronym>MOTIVATOR</trialacronym>
    <secondaryid>MTVR01-2015</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Coronary Artery Disease</healthcondition>
    <healthcondition>Non-ST elevation Myocardial Infarction</healthcondition>
    <healthcondition>Thrombolysed STEMI</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Coronary heart disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>High resolution catheter based laser imaging using optical coherence tomography (OCT) is used during coronary angiography. It is a routine procedure used in select patients (at the Cardiologists discretion) to view high resolution images from inside the blood vessels. The OCT imaging will add 10- 15 minutes to the angiogram procedure. 
A functional PET scan that detects the activity of coronary calcium build-up will take approximately 30 minutes. It is not a routine procedure. 
Blood samples will be taken at the baseline assessment (once consent is given) and stored to establish a bio-bank. The samples will be used investigate how fast atherosclerosis and calcium build-up occurs in the coronary arteries.
A CT-scan that determines 3-dimensional trajectory for calculation of stress distribution on artery walls is a commonly used imaging modality in patients. This scan also takes approximately 30 minutes.</interventions>
    <comparator>No group control</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Diagnosis / Prognosis</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Major Adverse Cardiac Events (Cardiovascular disease, death, MI, revascularisation). Via telephone follow-up and hospital records.</outcome>
      <timepoint>5 years post OCT.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Pathogenesis of plaque progression measured on CT scan within 30 days from OCT</outcome>
      <timepoint>Within 30 days post OCT</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Accuracy of OCT as a predictor of future MACE risk, assessed with OCT data and review of hospital records for MACE outcomes.</outcome>
      <timepoint>5 years post OCT</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients presenting to hospital with:
 NSTEMI proceeding to in-patient angiography
 STEMI proceeding to non-emergency in-patient angiography (late presentation or reperfused without PCI)
 All major epicardial coronary arteries suitable for for OCT prior to stenting (intervention).
The time point is during that hospital admission for the MI event. Simply in-patient angiography.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>eGFR &lt;40ml/min with diabetes mellitus
unlikely to survive for at least 3 years due to a co-morbidity
coronary anatomy unsuitable for OCT
pregnancy
prior coronary Bypass Graft
STEMI treated with PCI.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup>5</followup>
    <followuptype>Years</followuptype>
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>30/11/2015</anticipatedstartdate>
    <actualstartdate>30/11/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>100</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>WA</recruitmentstate>
    <hospital>Royal Perth Hospital - Perth</hospital>
    <postcode>6000 - Perth</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>University of Western Australia</primarysponsorname>
    <primarysponsoraddress>35 Stirling Highway, Crawley WA 6009</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Royal Perth Hospital Medical Research Foundation</fundingname>
      <fundingaddress>PO Box 2323, East Perth, WA 6892</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>None</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Patients who present with an acute coronary syndrome remain at high risk of further events in subsequent years.  Better identification of individuals at high risk can allow better targeting of novel therapies and resources. 
This study will create an imaging bio-bank that enables testing of multiple novel strategies involving new imaging, image analysis and biomarker approaches alone or in combination for improved risk stratification and targeting of prevention. 
Prospective follow-up in the cohort for outcomes enables the predictive value to be tested in a pilot data setting.
</summary>
    <trialwebsite>N/A</trialwebsite>
    <publication>N/A</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Royal Perth Hospital Human Research Ethics Committee</ethicname>
      <ethicaddress>Locked Bag 100, Palmyra DC WA 6961</ethicaddress>
      <ethicapprovaldate>20/08/2015</ethicapprovaldate>
      <hrec>REG 15-033</hrec>
      <ethicsubmitdate>4/03/2015</ethicsubmitdate>
      <ethiccountry />
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Carl Schultz</name>
      <address>Cardiology Department, Royal Perth Hospital 197 Wellington Street, Perth WA 6000</address>
      <phone>+61 (0) 8 9224 2067</phone>
      <fax />
      <email>carl.schultz@health.wa.gov.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Michelle Bonner</name>
      <address>Cardiology Research Department, Royal Perth Hospital 197 Wellington Street, Perth WA 6000</address>
      <phone>+61 (0) 8 9224 8609</phone>
      <fax />
      <email>michelle.bonner@health.wa.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Carl Schultz</name>
      <address>Cardiology Department, Royal Perth Hospital 197 Wellington Street, Perth WA 6000</address>
      <phone>+61 (0) 8 9224 2067</phone>
      <fax />
      <email>carl.schultz@health.wa.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Michelle Bonner</name>
      <address>Cardiology Research Department, Royal Perth Hospital 197 Wellington Street, Perth WA 6000</address>
      <phone>+61 (0) 8 9224 8609</phone>
      <fax />
      <email>michelle.bonner@health.wa.gov.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>